Breaking News Instant updates and real-time market news.

QCOM

Qualcomm

$68.19

0.65 (0.96%)

, HPQ

HP Inc.

$15.58

-0.02 (-0.13%)

07:32
10/10/16
10/10
07:32
10/10/16
07:32

Qualcomm appoints Ann Livermore to board of directors

Qualcomm (QCOM) announced the appointment of Ann Livermore to its Board of Directors. With her nearly 30 years at Hewlett-Packard (HPQ), Livermore brings extensive experience in senior leadership positions, and broad knowledge and experience in the areas of technology, business management, marketing, sales, and research and development. Livermore has been a director of United Parcel Services (UPS) since November 1997, and Hewlett Packard Enterprise (HPE) since November 2015. Livermore was a director of HP from June 2011 to November 2015.

QCOM

Qualcomm

$68.19

0.65 (0.96%)

HPQ

HP Inc.

$15.58

-0.02 (-0.13%)

HPE

HP Enterprise

$22.34

-0.285 (-1.26%)

UPS

UPS

$108.80

-0.32 (-0.29%)

  • 13

    Oct

  • 18

    Oct

  • 09

    Nov

  • 12

    Dec

  • 13

    Mar

QCOM Qualcomm
$68.19

0.65 (0.96%)

10/03/16
RBCM
10/03/16
NO CHANGE
Target $70
RBCM
Sector Perform
RBC says $120-130/share seems like high end of reasonable Qualcomm price for NXP
RBC analyst Amit Daryanani believes $120-$130 per share is likely the "upper end of the valuation framework" that Qualcomm (QCOM) would like to pay in any potential deal to acquire NXP Semiconductors (NXPI). While Qualcomm "can certainly elect to pay a larger premium" than that, doing so would likely come in the form of Qualcomm equity issuance, which would impede the accretion from the deal, Daryanani tells investors. The analyst keeps a Sector Perform rating on Qualcomm shares, but raised his price target on the stock to $70 from $59 citing the potential for diversification and higher cash flow generation that an NXP deal would provide.
10/03/16
UBSW
10/03/16
NO CHANGE
Target $59
UBSW
Neutral
Qualcomm acquisition of NXP Semiconductors would be positive, says UBS
UBS analyst Stephen Chin said he would view an acquisition of NXP Semiconductors (NXPI) by Qualcomm (QCOM) as positive citing such a deals likely accretion, as well as benefits like sales diversification, its patent portfolio and cash flow generation. Chin maintains his Neutral rating and $59 price target on Qualcomm shares.
09/30/16
OPCO
09/30/16
NO CHANGE
OPCO
NXP 'cheap' for Qualcomm even after rally, says Oppenheimer
Oppenheimer analyst Rick Schafer says NXP Semiconductors (NXPI) still a "cheap" takeover target for Qualcomm (QCOM) even after rallying 25% over the past two days. An acquisition would be accretive to Qualcomm's earnings "under most scenarios," the analyst tells investors in an intraday research note. He thinks Qualcomm needs to diversify away from handsets and has $31B of offshore cash, the analyst contends. Schafer keeps a Perform rating on Qualcomm.
10/06/16
MZHO
10/06/16
NO CHANGE
MZHO
Buy
Broadcom deal for Xilinx would 'open up' if Qualcomm buys NXP, says Mizuho
Mizuho analyst Vijay Rakesh believes that if Qualcomm (QCOM) acquires NXP Semiconductors (NXPI), as several recent media reports indicate the companies are moving toward, that it "opens up" a deal for Xilinx (XLNX) as an opportunity for Broadcom (AVGO). Rakesh has a Buy rating on Broadcom.
HPQ HP Inc.
$15.58

-0.02 (-0.13%)

08/25/16
MAXM
08/25/16
DOWNGRADE
Target $15
MAXM
Hold
HP Inc. downgraded to Hold on pressured printing margins at Maxim
As previously reported, Maxim analyst Nehal Chokshi downgraded HP Inc. to Hold from Buy and lowered his price target to $15 from $17, saying that his analysis points to sustained printing supplies pricing pressure despite the refresh of its printer hardware. Chokshi added that he expects the company to lower its FY17 earnings guidance at its Securities Analyst Meeting in October.
08/25/16
EVER
08/25/16
NO CHANGE
EVER
Micron has positive read through from HP statements, says Evercore ISI
After Hewlett-Packard (HPQ) said, "We are seeing on the horizon some shortages, particularly around LCDs, DRAM, and flash memory.," Evercore ISI analyst C.J. Muse says that the statement is positive for Micron. The analyst keeps a $16 price target and Buy rating on Micron.
08/25/16
MAXM
08/25/16
DOWNGRADE
MAXM
Hold
HP Inc. downgraded to Hold from Buy at Maxim
08/25/16
JEFF
08/25/16
NO CHANGE
Target $16.75
JEFF
Buy
HP gaining high-end PC share, positioning for future ink sales, says Jefferies
Jefferies analyst James Kisner noted that HP Inc. is gaining share in PCs at the high-end of the market and taking advantage of the weak Yen to place high value Printing units to drive future ink sales, both of which are trends that he likes. Kisner thinks HP shares will rise as the company delivers on its free cash flow targets and investors gain confidence in the improved trajectory of PCs and Supplies. The analyst increased his price target on HP to $16.75 from $16.00 and keeps a Buy rating on the name.
HPE HP Enterprise
$22.34

-0.285 (-1.26%)

09/08/16
09/08/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Apple (AAPL) downgraded to Market Perform from Outperform at Wells Fargo with analyst Maynard Um saying he views the risk/reward as balanced with the stock up 12% since Apple's earnings report on July 26. 2. Nike (NKE) downgraded to Neutral from Overweight at Piper Jaffray with analyst Erinn Murphy saying the resurgence of adidas (ADDYY) has taken a toll on Nike's growth rate in Germany, United Kingdom and France. 3. lululemon (LULU) downgraded to Hold from Buy at Jefferies with analyst Randal Konik saying the company's opportunity to grow its topline and expand operating margins are now largely factored into the stock. 4. Pier 1 Imports (PIR) downgraded to Underperform from Neutral at Credit Suisse, to Perform from Outperform at Oppenheimer, and to Market Perform from Strong Buy at Raymond James. 5. HP Enterprise (HPE) downgraded to Market Perform from Outperform at Wells Fargo with analyst Maynard Um citing a lack of near-term catalysts following the company's third quarter results. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/19/16
UBSW
09/19/16
NO CHANGE
Target $25
UBSW
Buy
HP Enterprise shares remain inexpensive, says UBS
UBS analyst Steven Milunovich noted investors concerns about HP Enterprise competition and believes the company's divestiture of services and software leaves it primarily as a hardware supplier with servers. storage, and networking. The analyst said the company believes they can innovate in hardware and provide complete solutions through its extensive partnerships, but he is giving the edge to their competitors. That said, he still believes the shares are undervalued. Milunovich reiterated his Buy rating and $24.50 price target on HP Enterprise shares.
09/19/16
BERN
09/19/16
NO CHANGE
BERN
HP Enterprise could be acquired after spin off, says Bernstein
After HP Enterprise said that it would do a tax free spin-merge of its software unit, Bernstein analyst A.M. Sacconaghi, Jr says that the remaining company could be acquired, given its relatively small valuation and the fact that its CEO is 60, has been at the company six years and has political ambitions. The analyst says that all of the potential strategic buyers of the remaining company "appear to have stumbling blocks." He thinks that an acquisition by private equity "might be more likely," and he views such a transaction as "doable." He keeps a $24.50 price target and Outperform rating on the shares.
09/08/16
OPCO
09/08/16
NO CHANGE
Target $25
OPCO
Outperform
HP Enterprise spinoff unlocks 'further value,' says Oppenheimer
Oppenheimer analyst Ittai Kidron says HP Enterprise reported another quarter of "solid execution," despite the soft revenue due to macro and end-market demand. Additionally, the company announced the spinoff of its Software segment, which the analyst views positively as it unlocks further value, eliminates a growth headwind, and allows the company to focus on hardware solutions. Kidron remains positive on HP Enterprise long term, but notes that a second large transaction further clouds the fundamental view of the company post spinoffs, possibly limiting near-term upside. He reiterates an Outperform rating and $25 price target on the shares.
UPS UPS
$108.80

-0.32 (-0.29%)

03/15/16
RBCM
03/15/16
NO CHANGE
RBCM
Amazon not yet capable of supplanting UPS, FedEx, says RBC Capital
Noting that Amazon (AMZN) has recently begun to procure and manage freight transportation internally, causing investors to become concerned that the company is looking to supplant UPS (UPS) and FedEx (FDX), RBC Capital says it does not think the e-commerce giant is currently capable of building a "full-scale pickup and delivery business." However, the firm does believe that Amazon is looking to "create a limited pickup and delivery operation" that will incentivize UPS and FedEx to keep their prices low and service levels high. RBC also thinks that Amazon is looking to reduce its costs by building a global supply chain. RBC believes that FedEx and UPS could be threatened by Amazon's move over the longer term ,but it says that the shipping companies will have time to react to Amazon's initiatives before they present a major threat.
04/11/16
UBSW
04/11/16
NO CHANGE
Target $186
UBSW
Buy
FedEx valuation gap to UPS still too wide, says UBS
UBS analyst Thomas Wadewitz noted that the valuation gap between shares of FedEx (FDX) and UPS (UPS) on a price-to-earnings basis is still well above the historical average even after the run-up in FedEx shares since the company's Q3 report. The analyst, who expects margin improvement at Express, volume growth at Ground, and accretion from the TNT (TNTEY) deal to support EPS growth, keeps a Buy rating and $186 price target on FedEx shares.
05/26/16
BERN
05/26/16
NO CHANGE
BERN
UPS, FedEx to continue to see growing e-commerce demand, says Bernstein
Bernstein believes that Amazon and other retailers will continue to rely less on UPS (UPS) and FedEx (FDX) going forward. However, the firm still estimates that the volume of e-commerce deliveries by the two companies will nevertheless rise 7%-10% annually. The firm expects the total domestic market for the national carries to rise by 3%-5% in future years. It keeps an Outperform rating on UPS and a Market Perform rating on FedEx.
08/01/16
OPCO
08/01/16
NO CHANGE
Target $116
OPCO
Outperform
UPS price target raised to $116 from $112 at Oppenheimer
Oppenheimer analyst Scott Schneeberger raised his price target for UPS to $116 from $112 following a "solid" Q2 and maintained outlook. The analyst believes that the UPS story remains on track and reiterates an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

CELG

Celgene

$117.63

-1.24 (-1.04%)

22:25
12/04/16
12/04
22:25
12/04/16
22:25
Conference/Events
Celgene to hold an analyst and investor event »

Management holds an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

AAPL

Apple

$109.90

0.41 (0.37%)

, ALNY

Alnylam

$41.57

-0.01 (-0.02%)

21:48
12/04/16
12/04
21:48
12/04/16
21:48
Hot Stocks
On The Fly: Top five weekend stock stories »

Catch up on the…

AAPL

Apple

$109.90

0.41 (0.37%)

ALNY

Alnylam

$41.57

-0.01 (-0.02%)

BLCM

Bellicum Pharmaceuticals

$18.72

1.74 (10.25%)

SGEN

Seattle Genetics

$66.70

-0.01 (-0.01%)

CELG

Celgene

$117.63

-1.24 (-1.04%)

UTX

United Technologies

$108.22

0.74 (0.69%)

RXN

Rexnord

$20.27

-0.72 (-3.43%)

ETP

Energy Transfer Partners

$34.38

1.16 (3.49%)

EVC

Entravision

TJX

TJX

$77.10

-0.57 (-0.73%)

FL

Foot Locker

$74.23

0.55 (0.75%)

DE

Deere

$101.50

-1.2 (-1.17%)

ARCH

Arch Coal

$79.32

1.6 (2.06%)

ELY

Callaway Golf

$11.68

-0.3 (-2.50%)

GME

GameStop

$24.27

-0.37 (-1.50%)

AEO

American Eagle

$16.17

-0.57 (-3.41%)

JCP

J.C. Penney

$9.81

0.28 (2.94%)

GOOG

Alphabet

$750.50

2.58 (0.34%)

GOOGL

Alphabet Class A

$764.46

0.13 (0.02%)

MRK

Merck

$61.13

0.37 (0.61%)

DIS

Disney

$98.50

-0.44 (-0.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 05

    Dec

  • 05

    Dec

  • 05

    Dec

  • 06

    Dec

  • 09

    Jan

  • 15

    Jan

  • 08

    Mar

  • 13

    Mar

TRIP

TripAdvisor

$46.46

-0.7 (-1.48%)

21:40
12/04/16
12/04
21:40
12/04/16
21:40
Upgrade
TripAdvisor rating change  »

TripAdvisor upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTXS

Citrix

$85.62

0.15 (0.18%)

21:40
12/04/16
12/04
21:40
12/04/16
21:40
Upgrade
Citrix rating change  »

Citrix upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 07

    Dec

  • 08

    Dec

XOM

Exxon Mobil

$87.04

-0.2 (-0.23%)

21:12
12/04/16
12/04
21:12
12/04/16
21:12
Periodicals
Trump widens Secretary of State search, will interview Exxon Mobil CEO, WSJ says »

President-elect Donald…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

NVS

Novartis

$68.17

0.42 (0.62%)

, JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

21:08
12/04/16
12/04
21:08
12/04/16
21:08
Periodicals
Novartis CEO downplays possibility of Actelion bid, Reuters says »

Asked whether Novartis…

NVS

Novartis

$68.17

0.42 (0.62%)

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

ALIOF

Actelion

$206.01

15.21 (7.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

PCRFY

Panasonic

$10.58

0.19 (1.83%)

21:05
12/04/16
12/04
21:05
12/04/16
21:05
Periodicals
Panasonic eyes European headlight maker ZKW, Nikkei says »

Panasonic plans to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$109.90

0.41 (0.37%)

21:03
12/04/16
12/04
21:03
12/04/16
21:03
Hot Stocks
Apple comments on U.S. autonomous cars policy, says 'excited' about potential »

The U.S.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Mar

ETP

Energy Transfer Partners

$34.38

1.16 (3.49%)

20:46
12/04/16
12/04
20:46
12/04/16
20:46
Hot Stocks
Army says will not grant easement for Dakota Access Pipeline »

The Department of the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INCY

Incyte

$102.02

2.09 (2.09%)

, PFE

Pfizer

$31.63

0.17 (0.54%)

20:25
12/04/16
12/04
20:25
12/04/16
20:25
Conference/Events
Canaccord biotech analyst to hold a dinner meeting »

In conjunction with the…

INCY

Incyte

$102.02

2.09 (2.09%)

PFE

Pfizer

$31.63

0.17 (0.54%)

LLY

Eli Lilly

$67.71

1.74 (2.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

  • 15

    Dec

AGIO

Agios Pharmaceuticals

$56.97

-1.09 (-1.88%)

20:11
12/04/16
12/04
20:11
12/04/16
20:11
Hot Stocks
Agios Pharmaceuticals reports data on AG-348, AG-519 »

Agios Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

KPTI

Karyopharm

$9.28

0.25 (2.77%)

19:59
12/04/16
12/04
19:59
12/04/16
19:59
Hot Stocks
Karyopharm reports updated Phase 2b STORM data »

Karyopharm Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

, ABBV

AbbVie

$59.43

0.27 (0.46%)

19:56
12/04/16
12/04
19:56
12/04/16
19:56
Hot Stocks
AbbVie reports data from two IMBRUVICA combination studies »

AbbVie (ABBV) announced…

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

ABBV

AbbVie

$59.43

0.27 (0.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 06

    Dec

BPMC

Blueprint Medicines

$27.01

-0.99 (-3.54%)

19:50
12/04/16
12/04
19:50
12/04/16
19:50
Hot Stocks
Blueprint Medicines reports Phase 1 BLU-285 data »

Blueprint Medicines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

INCY

Incyte

$102.02

2.09 (2.09%)

19:45
12/04/16
12/04
19:45
12/04/16
19:45
Hot Stocks
Incyte reports pooled analysis of five-year Jakafi data »

Incyte announced an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

GPRO

GoPro

$9.70

-0.12 (-1.22%)

19:42
12/04/16
12/04
19:42
12/04/16
19:42
Hot Stocks
GoPro releases $299 'Karma Grip' camera stabilizer »

GoPro announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 07

    Dec

  • 12

    Dec

KPTI

Karyopharm

$9.28

0.25 (2.77%)

19:37
12/04/16
12/04
19:37
12/04/16
19:37
Hot Stocks
Karyopharm reports data from Phase 2 SAIL study »

Karyopharm Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

CELG

Celgene

$117.63

-1.24 (-1.04%)

19:32
12/04/16
12/04
19:32
12/04/16
19:32
Hot Stocks
Acetylon reports preclinical ACY-957 data »

Acetylon Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

GBT

Global Blood Therapeutics

$19.10

-0.1 (-0.52%)

19:30
12/04/16
12/04
19:30
12/04/16
19:30
Hot Stocks
Global Blood Therapeutics reports Phase 1/2 GBT440 data »

Global Blood Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 05

    Dec

  • 14

    Dec

  • 15

    Dec

  • 19

    Dec

CELG

Celgene

$117.63

-1.24 (-1.04%)

19:27
12/04/16
12/04
19:27
12/04/16
19:27
Hot Stocks
Acetylon reports initial Phase 1a/b data for citarinostat in myeloma »

Acetylon Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

XLRN

Acceleron

$36.29

1.25 (3.57%)

, CELG

Celgene

$117.63

-1.24 (-1.04%)

19:23
12/04/16
12/04
19:23
12/04/16
19:23
Hot Stocks
Acceleron, Celgene report updated data from Phase 2 luspatercept studies »

Acceleron Pharma (XLRN)…

XLRN

Acceleron

$36.29

1.25 (3.57%)

CELG

Celgene

$117.63

-1.24 (-1.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 04

    Dec

  • 05

    Dec

  • 06

    Dec

ALNY

Alnylam

$41.57

-0.01 (-0.02%)

19:05
12/04/16
12/04
19:05
12/04/16
19:05
Hot Stocks
Alnylam reports Phase 2 data on fitusiran in hemophilia »

Alnylam Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALXN

Alexion

$122.96

0.95 (0.78%)

19:01
12/04/16
12/04
19:01
12/04/16
19:01
Hot Stocks
Alexion reports data from Phase 1/2 ALXN1210 study »

Alexion Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 14

    Dec

LYV

Live Nation

$27.07

-0.44 (-1.60%)

18:58
12/04/16
12/04
18:58
12/04/16
18:58
Hot Stocks
Live Nation acquires 51% stake in Australia's Secret Sounds Group »

Live Nation Entertainment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVS

Novartis

$68.17

0.42 (0.62%)

18:45
12/04/16
12/04
18:45
12/04/16
18:45
Hot Stocks
Novartis reports Phase 2 data on CTL019 in leukemia »

Novartis announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.